Regeneron Pharmaceuticals, Inc.
REGNLast close · Oct 16, 2026790.74−5.60 (−0.70%)
Market cap$81.4B
Between Aug 18, 2026 and Oct 14, 2026, Regeneron (REGN) insiders filed 40 Form 4 transactions: 30 sales worth $5.5M in total and no open-market purchase; 30 of the sales were under 10b5-1 plans set in advance. The largest seller was Mccourt Marion, $1.0M. 10 other filings were grants, exercises or gifts, which say nothing about buying or selling.
40
0
30
35
Form 4 transactions
| Date | Insider | Title | Code | Plan | Shares | Price | Value |
|---|---|---|---|---|---|---|---|
| 2026-10-13 | MURPHY ANDREW J | Co-Chief Scientific Officer | M | 10b5-1 | 17,000 | 0.00 | $0 |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | S | 10b5-1 | 50 | 781.47 | $39,073.5 |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | S | 10b5-1 | 463 | 780.63 | $361,431.7 |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | S | 10b5-1 | 380 | 779.59 | $296,244.2 |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | S | 10b5-1 | 454 | 778.64 | $353,502.6 |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | S | 10b5-1 | 38 | 777.76 | $29,554.9 |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | S | 10b5-1 | 66 | 776.31 | $51,236.5 |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | S | 10b5-1 | 376 | 775.46 | $291,573 |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | S | 10b5-1 | 121 | 774.48 | $93,712.1 |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | S | 10b5-1 | 224 | 773.40 | $173,241.6 |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | S | 10b5-1 | 211 | 772.56 | $163,010.2 |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | S | 10b5-1 | 283 | 771.56 | $218,351.5 |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | S | 10b5-1 | 12 | 770.20 | $9,242.4 |
| 2026-10-13 | MURPHY ANDREW J | Co-Chief Scientific Officer | M | 10b5-1 | 17,000 | 381.92 | $6.5M |
| 2026-10-13 | MURPHY ANDREW J | Co-Chief Scientific Officer | F | 10b5-1 | 12,853 | 754.58 | $9.7M |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | S | 10b5-1 | 6 | 753.76 | $4,522.6 |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | S | 10b5-1 | 35 | 755.91 | $26,456.9 |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | S | 10b5-1 | 16 | 757.68 | $12,122.9 |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | S | 10b5-1 | 24 | 758.16 | $18,195.8 |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | S | 10b5-1 | 14 | 759.96 | $10,639.4 |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | S | 10b5-1 | 74 | 760.65 | $56,288.1 |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | S | 10b5-1 | 27 | 761.36 | $20,556.7 |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | S | 10b5-1 | 55 | 762.57 | $41,941.4 |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | S | 10b5-1 | 25 | 763.76 | $19,094 |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | S | 10b5-1 | 219 | 764.40 | $167,403.6 |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | S | 10b5-1 | 271 | 765.39 | $207,420.7 |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | S | 10b5-1 | 279 | 766.47 | $213,845.1 |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | S | 10b5-1 | 192 | 767.39 | $147,338.9 |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | S | 10b5-1 | 105 | 768.33 | $80,674.7 |
| 2026-10-14 | MURPHY ANDREW J | Co-Chief Scientific Officer | S | 10b5-1 | 127 | 769.30 | $97,701.1 |
| 2026-09-02 | McCourt Marion | EVP Commercial | S | 10b5-1 | 1,215 | 850.00 | $1.0M |
| 2026-09-03 | McCourt Marion | EVP Commercial | S | 10b5-1 | 1,131 | 857.39 | $969,708.1 |
| 2026-09-02 | Guarini Kathryn | Director | M | 10b5-1 | 400 | 719.37 | $287,748 |
| 2026-09-02 | Guarini Kathryn | Director | S | 10b5-1 | 400 | 850.00 | $340,000 |
| 2026-09-02 | Guarini Kathryn | Director | M | 10b5-1 | 400 | 0.00 | $0 |
| 2026-08-19 | LAROSA JOSEPH J | EVP General Counsel and Secret | M | 12,282 | 381.92 | $4.7M | |
| 2026-08-19 | LAROSA JOSEPH J | EVP General Counsel and Secret | F | 9,019 | 830.15 | $7.5M | |
| 2026-08-19 | LAROSA JOSEPH J | EVP General Counsel and Secret | M | 12,282 | 0.00 | $0 | |
| 2026-08-18 | Fenimore Christopher R. | EVP Finance CFO | M | 6,283 | 381.92 | $2.4M | |
| 2026-08-18 | Fenimore Christopher R. | EVP Finance CFO | F | 4,599 | 813.47 | $3.7M |
Codes are the SEC's: P open-market purchase, S open-market sale; M exercise, F tax withholding, A grant and G gift are routine. A 10b5-1 flag means the trade ran under a plan adopted in advance. Method notes in where the numbers come from.